Biocon, Asia's premier biotechnology company, is all set to tap the US markets as the company is planning to sell its anti-cholesterol drug- atorvastatin- in the US from Financial Year (FY) 2013.
The US market for atorvastatin has recently opened up for generic companies. Further, the company plans to follow Watson and Ranbaxy, which have already launched their products in the markets and are currently under six months exclusivity phase.
The company has seen a significant growth in branded atorvastatin (Statix) as well as sales of active pharmaceutical ingredients (API). Similarly, Biocon is also planning to tap the European market, where it is currently selling atorvastatin with its partners. Biocon has major presence in emerging and unregulated markets with its branded atorvastatin (Statix).
Biocon is Asia’s leading R&D based Biotechnology Company. It produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies. The drug major also produces mycophenolate mofetil, sirolimus and tacrolimus.
